Intrivo Diagnostics Secures National Distribution Agreement with McKesson Medical-Surgical for Access Bio CareStart™ COVID-19 Tests
LOS ANGELES, Dec. 17, 2020
NDC, Inc. as key national partners within the Healthcare Supply Chain to help bring the CareStart™ line of COVID-19 testing products to the US market.
“Our agreement with McKesson Medical-Surgical is a monumental step in our efforts to reopen America through the use of rapid testing on a mass scale. By enhancing our supply chain to ensure greater access to Access Bio’s testing products, we can play a large role in curbing the spread of this virus,” said Reeve Benaron, Founder, Chairman and CEO, Intrivo Diagnostics. “We are delighted to welcome McKesson to our family of authorized distributors.”
Ginkgo Bioworks Funds Expansion of Rapid Antigen Test Manufacturing with Access Bio in New Jersey
November 22, 2020
Securing access to 10 million rapid antigen tests, which are EUA authorized and available today through Concentric by Ginkgo
BOSTON, Nov. 20, 2020 /PRNewswire/ Today, Ginkgo Bioworks announced it has secured access to at least 10 million rapid antigen test kits from Access Bio, a global in vitro diagnostics company. The tests will be available through Concentric by Ginkgo, the company’s end-to-end service for COVID-19 testing, for organizations seeking to use testing as part of their broader public health strategies. Additionally, Ginkgo provided capital to expand manufacturing capacity at Access Bio’s New Jersey factory for production of rapid diagnostic tests.
NDC, Inc. as key national partners within the Healthcare Supply Chain to help bring the CareStart™ line of COVID-19 testing products to the US market.
“Our agreement with McKesson Medical-Surgical is a monumental step in our efforts to reopen America through the use of rapid testing on a mass scale. By enhancing our supply chain to ensure greater access to Access Bio’s testing products, we can play a large role in curbing the spread of this virus,” said Reeve Benaron, Founder, Chairman and CEO, Intrivo Diagnostics. “We are delighted to welcome McKesson to our family of authorized distributors.”
As Access Bio’s exclusive US commercialization partner, Intrivo’s new channel agreements will expand the supply chain for the
Intrivo Diagnostics Secures National Distribution Agreement with McKesson Medical-Surgical for Access Bio CareStart(TM) COVID-19 Tests marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
Letter: A better COVID testing strategy
Published: 12/16/2020 12:01:45 AM
It is amazing that the White House has not had a COVID outbreak from March until October. This is despite the fact that the White House and its events are mostly non-mask-wearing and ignore public health practices. This has been done mostly through the use of the Binax and the Access Bio COVID Antigen tests. Even though these tests may have less accuracy, they have demonstrated they are effective.
We have largely medicalized COVID testing. Get a prescription, wait in line, and wait up to three days for a result. At a private business, expect to pay up to $180 per test. Not quite as actionable as if you did it after brushing your teeth.